The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 27, 2024

Filed:

Mar. 15, 2022
Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Tracy Chia-Chien Kuo, San Mateo, CA (US);

Bijan Andre Boldajipour, San Francisco, CA (US);

Javier Fernando Chaparro Riggers, San Mateo, CA (US);

Philippe Duchateau, Draveil, FR;

Roman Galetto, Paris, FR;

Alexandre Juillerat, New York, NY (US);

Thomas Charles Pertel, San Mateo, CA (US);

Arvind Rajpal, San Francisco, CA (US);

Barbra Johnson Sasu, San Francisco, CA (US);

Cesar Adolfo Sommer, San Mateo, CA (US);

Julien Valton, Charenton le Pont, FR;

Thomas John Van Blarcom, Oakland, CA (US);

Assignee:

PFIZER INC., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C12N 5/10 (2006.01); C07K 14/725 (2006.01); A61K 31/7076 (2006.01); C12N 15/63 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 31/7076 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/46 (2023.05); A61K 39/4631 (2023.05); A61K 39/464417 (2023.05); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2896 (2013.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 16/2863 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2510/02 (2013.01);
Abstract

The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).


Find Patent Forward Citations

Loading…